PPBT
Purple Biotech·NASDAQ
--
--(--)
--
--(--)
PPBT fundamentals
During Q4 2025, Purple Biotech (PPBT) reported revenue of --, a YoY change of 0.00%. Net income was -23.64M, a YoY change of -5596.87%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2021 | Q2,2021 | Q3,2021 | Q4,2021 | Q1,2022 | Q2,2022 | Q3,2022 | Q4,2022 | Q1,2023 | Q2,2023 | Q3,2023 | Q4,2023 | Q1,2024 | Q2,2024 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | TTM |
|---|
Start Date | Jan 1, 2021 | Apr 1, 2021 | Jul 1, 2021 | Oct 1, 2021 | Jan 1, 2022 | Apr 1, 2022 | Jul 1, 2022 | Oct 1, 2022 | Jan 1, 2023 | Apr 1, 2023 | Jul 1, 2023 | Oct 1, 2023 | Jan 1, 2024 | Apr 1, 2024 | Jul 1, 2024 | Oct 1, 2024 | Jan 1, 2025 | Apr 1, 2025 | Jul 1, 2025 | Oct 1, 2025 | -- |
End Date | Mar 31, 2021 | Jun 30, 2021 | Sep 30, 2021 | Dec 31, 2021 | Mar 31, 2022 | Jun 30, 2022 | Sep 30, 2022 | Dec 31, 2022 | Mar 31, 2023 | Jun 30, 2023 | Sep 30, 2023 | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | -- |
Fiscal Year-End | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | -- |
Operating Expenses | 6.53M -- | 3.62M -- | 3.04M -- | 4.74M -- | 7.33M +12.25% | 3.59M -0.88% | 5.08M +67.03% | 6.60M +39.29% | 5.12M -30.13% | 5.13M +43.04% | 5.75M +13.11% | 6.27M -5.06% | 4.47M -12.81% | 3.46M -32.66% | 2.13M -62.88% | 1.02M -83.79% | 1.41M -68.52% | 1.24M -64.26% | 1.37M -35.91% | 23.45M +2207.68% | 27.45M -- |
Selling, General and Administrative Expenses | 1.66M -- | 1.53M -- | 1.42M -- | 1.49M -- | 1.38M -16.78% | 1.51M -1.82% | 1.62M +13.72% | 1.78M +19.21% | 1.62M +17.77% | 1.43M -5.11% | 1.16M -28.34% | 1.02M -42.45% | 1.04M -35.78% | 865.00K -39.51% | 785.00K -32.21% | 558.00K -45.56% | 646.00K -38.06% | 683.00K -21.04% | 780.00K -0.64% | 1.14M +103.41% | 3.24M -- |
General and Administrative Expenses | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 5.24M -- | 1.04M -- | -- -- | -- -- | -- -- | 646.00K -38.06% | -- -- | -- -- | -- -- | -- -- |
Research and Development Expenses | 4.87M -- | 2.09M -- | 1.62M -- | 3.25M -- | 5.95M +22.12% | 2.08M -0.19% | 3.46M +113.76% | 4.82M +48.54% | 3.50M -41.23% | 3.71M +77.87% | 4.59M +32.44% | 5.24M +8.76% | 3.42M -2.14% | 2.39M -35.47% | 1.35M -70.63% | 458.00K -91.26% | 760.00K -77.80% | 553.00K -76.87% | 587.00K -56.45% | 1.83M +299.34% | 3.73M -- |
Loss on Impairment of Other Assets | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 0 -- | -- -- | 0 -- | 0 -- | 0 -- | -- -- | 202.00K -- | -- -- | 0 -- | -- -- | 0 -100.00% | -- -- | 20.48M -- | -- -- |
Operating Income | -6.53M -- | -3.62M -- | -3.04M -- | -4.74M -- | -7.33M -12.25% | -3.59M +0.88% | -5.08M -67.03% | -6.60M -39.29% | -5.12M +30.13% | -5.13M -43.04% | -5.75M -13.11% | -6.27M +5.06% | -4.47M +12.81% | -3.46M +32.66% | -2.13M +62.88% | -1.02M +83.79% | -1.41M +68.52% | -1.24M +64.26% | -1.37M +35.91% | -23.45M -2207.68% | -27.45M -- |
Non-Operating Income (Loss) | 98.00K -- | -24.00K -- | 47.00K -- | -13.00K -- | 15.00K -84.69% | 38.00K +258.33% | 232.00K +393.62% | 558.00K +4392.31% | 219.00K +1360.00% | -25.00K -165.79% | 692.00K +198.28% | 1.41M +152.33% | 685.00K +212.79% | 1.04M +4272.00% | 1.47M +111.71% | 601.00K -57.32% | 950.00K +38.69% | 147.00K -85.91% | 62.00K -95.77% | -196.00K -132.61% | 963.00K -- |
Gain (Loss) on Change in Fair Value | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | 3.50M -- | -- -- | -- -- | -- -- | 76.00K -97.83% | -- -- | -- -- | -- -- | -61.00K -180.26% | -- -- |
Net Interest Expense | -98.00K -- | 24.00K -- | -47.00K -- | 13.00K -- | -15.00K +84.69% | -38.00K -258.33% | -232.00K -393.62% | -558.00K -4392.31% | -219.00K -1360.00% | 25.00K +165.79% | -692.00K -198.28% | 2.09M +474.37% | -685.00K -212.79% | -1.04M -4272.00% | -1.47M -111.71% | -525.00K -125.13% | -950.00K -38.69% | -147.00K +85.91% | -62.00K +95.77% | 135.00K +125.71% | -1.02M -- |
Interest Expense | 20.00K -- | 102.00K -- | 21.00K -- | 69.00K -- | 41.00K +105.00% | 51.00K -50.00% | 16.00K -23.81% | -41.00K -159.42% | 59.00K +43.90% | 148.00K +190.20% | 16.00K -- | 1.97M +4909.76% | 17.00K -71.19% | 24.00K -83.78% | 511.00K +3093.75% | -69.00K -103.50% | 35.00K +105.88% | 0 -100.00% | 61.00K -88.06% | 214.00K +410.14% | 310.00K -- |
Interest Income | 118.00K -- | 78.00K -- | 68.00K -- | 56.00K -- | 56.00K -52.54% | 89.00K +14.10% | 248.00K +264.71% | 517.00K +823.21% | 278.00K +396.43% | 123.00K +38.20% | 708.00K +185.48% | -117.00K -122.63% | 702.00K +152.52% | 1.07M +767.48% | 1.98M +179.10% | 456.00K +489.74% | 985.00K +40.31% | 147.00K -86.22% | 123.00K -93.78% | 79.00K -82.68% | 1.33M -- |
Pretax Income From Continuing Operations | -6.43M -- | -3.65M -- | -3.00M -- | -4.75M -- | -7.32M -13.73% | -3.55M +2.58% | -4.85M -61.90% | -6.04M -27.17% | -4.90M +32.98% | -5.16M -45.27% | -5.05M -4.25% | -4.86M +19.59% | -3.78M +22.88% | -2.42M +53.20% | -668.00K +86.79% | -415.00K +91.46% | -456.00K +87.94% | -1.09M +54.91% | -1.30M -95.36% | -23.64M -5596.87% | -26.49M -- |
Income from Discontinued Operations | -136.00K -- | 2.00K -- | -154.00K -- | -354.00K -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- |
Net Income | -6.57M -- | -3.64M -- | -3.15M -- | -5.11M -- | -7.32M -11.37% | -3.55M +2.52% | -4.85M -53.99% | -6.04M -18.35% | -4.90M +32.98% | -5.16M -45.27% | -5.05M -4.25% | -4.86M +19.59% | -3.78M +22.88% | -2.42M +53.20% | -668.00K +86.79% | -415.00K +91.46% | -456.00K +87.94% | -1.09M +54.91% | -1.30M -95.36% | -23.64M -5596.87% | -26.49M -- |
Net Income Attributable to Minority Interests | -22.00K -- | -16.00K -- | -12.00K -- | -34.00K -- | -19.00K +13.64% | -16.00K -- | -25.00K -108.33% | -32.00K +5.88% | -25.00K -31.58% | -22.00K -37.50% | -19.00K +24.00% | -31.00K +3.13% | -19.00K +24.00% | -10.00K +54.55% | -5.00K +73.68% | -5.00K +83.87% | -3.00K +84.21% | -4.00K +60.00% | -2.00K +60.00% | -97.00K -1840.00% | -106.00K -- |
Net Income Attributable to Owners of the Company | -6.55M -- | -3.63M -- | -3.14M -- | -5.07M -- | -7.30M -11.46% | -3.54M +2.54% | -4.82M -53.78% | -6.01M -18.51% | -4.88M +33.15% | -5.14M -45.31% | -5.04M -4.39% | -4.83M +19.68% | -3.76M +22.88% | -2.40M +53.19% | -663.00K +86.83% | -410.00K +91.51% | -453.00K +87.96% | -1.08M +54.89% | -1.30M -96.53% | -23.55M -5642.93% | -26.39M -- |
Net Income Attributable to Common Stockholders | -6.55M -- | -3.63M -- | -3.14M -- | -5.07M -- | -7.30M -11.46% | -3.54M +2.54% | -4.82M -53.78% | -6.01M -18.51% | -4.88M +33.15% | -5.14M -45.31% | -5.04M -4.39% | -4.83M +19.68% | -3.76M +22.88% | -2.40M +53.19% | -663.00K +86.83% | -410.00K +91.51% | -453.00K +87.96% | -1.08M +54.89% | -1.30M -96.53% | -23.55M -5642.93% | -26.39M -- |
Other Comprehensive Income | -- -- | -- -- | -- -- | -- -- | -- -- | -21.00K -- | 4.00K -- | 11.00K -- | 1.00K -- | 5.00K +123.81% | -- -- | 21.00K +90.91% | -15.00K -1600.00% | -6.00K -220.00% | -- -- | 2.00K -90.48% | -- -- | -- -- | -- -- | 0 -100.00% | -- -- |
Total Comprehensive Income | -6.57M -- | -3.64M -- | -3.15M -- | -5.11M -- | -7.32M -11.37% | -3.57M +1.95% | -4.84M -53.86% | -6.03M -18.14% | -4.90M +33.00% | -5.16M -44.28% | -5.05M -4.33% | -4.84M +19.79% | -3.80M +22.56% | -2.42M +53.04% | -668.00K +86.79% | -413.00K +91.46% | -456.00K +87.99% | -1.09M +55.02% | -1.30M -95.36% | -23.64M -5624.46% | -26.49M -- |
Total Comprehensive Income Attributable to Minority Interests | -- -- | -16.00K -- | -12.00K -- | -34.00K -- | -- -- | -16.00K -- | -25.00K -108.33% | -32.00K +5.88% | -25.00K -- | -22.00K -37.50% | -19.00K +24.00% | -31.00K +3.13% | -19.00K +24.00% | -10.00K +54.55% | -5.00K +73.68% | -5.00K +83.87% | -3.00K +84.21% | -4.00K +60.00% | -2.00K +60.00% | -97.00K -1840.00% | -106.00K -- |
Total Comprehensive Income Attributable to Owners of the Company | -6.57M -- | -3.63M -- | -3.14M -- | -5.07M -- | -7.32M -11.37% | -3.56M +1.96% | -4.82M -53.65% | -6.00M -18.30% | -4.88M +33.34% | -5.13M -44.31% | -5.04M -4.48% | -4.81M +19.88% | -3.78M +22.55% | -2.41M +53.03% | -663.00K +86.83% | -408.00K +91.51% | -453.00K +88.01% | -1.08M +55.00% | -1.30M -96.53% | -23.55M -5671.08% | -26.39M -- |
Basic EPS | -0.04 -- | -0.02 -- | -0.02 -- | -0.03 -- | 0 +100.00% | 0 +100.00% | -0.03 -50.00% | -0.03 -- | -0.02 -- | -0.02 -- | -0.46 -1433.33% | -0.02 +33.33% | -0.28 -1300.00% | -0.01 +50.00% | 0 +100.00% | 0 +100.00% | 0 +100.00% | 0 +100.00% | 0 -- | -0.1 -- | -0.1 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.25 -- | -4.63 -- | -- -- | -0.28 -- | -1.8 -620.00% | 0 +100.00% | -2 -- | -0.17 +39.29% | -0.4 +77.78% | 0 -- | -19.85 -892.50% | -20.42 -- |
Diluted EPS | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.01 -- | 0 -- | 0 -- | -- -- | 0 +100.00% | 0 -- | -0.1 -- | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -- -- | -0.25 -- | -4.63 -- | -- -- | -0.28 -- | -1.8 -620.00% | 0 +100.00% | -2 -- | -0.17 +39.29% | -0.4 +77.78% | 0 -- | -19.85 -892.50% | -20.42 -- |
You can ask Aime
Did Purple Biotech beat or miss consensus estimates last quarter?What were the key takeaways from Purple Biotech’s earnings call?What were the key takeaways from Purple Biotech's earnings call?What factors drove the changes in Purple Biotech's revenue and profit?What is the market's earnings forecast for Purple Biotech next quarter?What is Purple Biotech's latest dividend and current dividend yield?What is Purple Biotech's gross profit margin?What guidance did Purple Biotech's management provide for the next earnings period?
